Indian foreign investment debate hots up
This article was originally published in Scrip
The Indian pharma foreign direct investment (FDI) debate – something of a dormant volcano – erupted again toward the fag end of 2014, after a Parliamentary panel took a tough view on such inflows in the case of brownfield deals, only to be followed by reports of the finance ministry seemingly singing a different tune.
You may also be interested in...
India has eased foreign direct investment (FDI) norms in the pharmaceutical sector – reforms that are expected to buoy foreign capital inflows and investor sentiment, especially private equity, though some opponents claim it may potentially have a dire impact on India's future medicines security.
Biocon’s itolizumab gets clearance in India for restricted emergency use in COVID-19 patients, amid some concerns around small study numbers. But company says data are compelling and cites compassionate use substantiation, while partner Equillium expects to pursue a global study under US IND.
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.